Skip Navigation

European Heart Journal 1989 10(6):502-508;
Copyright © 1989 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by RIZZON, P.
Right arrow Articles by CORSI, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by RIZZON, P.
Right arrow Articles by CORSI, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1989 The European Society of Cardiology

High doses of L-carnitine in acute myocardial infarction: metabolic and antiarrhythmic effects

P. RIZZON, G. BIASCO, M. DI BIASE, F. BOSCIA, U. RIZZO, F. MINAFRA, A. BORTONE, N. SILIPRANDI*, A. PROCOPIO{dagger}, E. BAGIELLA{ddagger} and M. CORSI

Cattedra di Cardiologia, University of Bari Sigma-fau S.p.A., Rome, Italy
*lstituto di Chimica Biologica, University of Padua Sigma-fau S.p.A., Rome, Italy
{dagger}Laboratorio di Analisi Ospedale Spallanzani, Rome
{ddagger}Informatic and Biostatic Department Sigma-fau S.p.A., Rome, Italy
Clinical Research Department Sigma-fau S.p.A., Rome, Italy

Received 25 March 1988; accepted 27 September 1988.

Address for reprints. Prof. P. Rizzon, Clinica Medical I Cardiologia, Policlinico, 70124 Bari, Italy.

Abstract

Fatty acids accumulate in the muscle cells in some carnitine deficiency syndromes due to a variety of genetic defects in intermediary metabolism. L-Carnitine administration may relieve this excess by transporting acyl compounds out of the cell as acylcarnitine. Similar fatty acid accumulation occurs during myocardial ischae-mia because of the decreased rate of fi-oxidation, and this has been put forward as a cause of ventricular arrhythmias. This study was carried out to investigate whether administration of high doses of i.v. L-carnitine in patients with acute myocardial infarction could increase urinary excretion of acylcarnitine and reduce early ventricular arrhythmias.

Fifty-six patients suffering from acute myocardial infarction, admitted to the Coronary Unit between 3 and 12 h after the onset of symptoms, were included in the study.

The design of the study was double blind, parallel and placebo controlled. Allocation of treatment to patients was done randomly after stratification (time from onset of pain and site of infarction). The first group (28 patients) received intravenous L-carnitine at a dose of 100 mg kg–1 b.w. every 12 h for 36 h while the second group (28 patients) received placebo intravenously. Immediately before starting treatment two blood samples were taken (at 5-min intervals) and a further 16 samples were taken at regular intervals over the following 48 h. Patients' urine was collected over the same period of time. Concentrations of free carnitine, short chain acylcarnitine esters and long chain acylcarnitine esters in serum and urine were measured. On days 1 and 2, 24-h ECG monitoring (Holler) was carried out.

Analysis of results showed that: (1) in patients receiving placebo, free carnitine serum levels increased significantly during the first 48 h after infarction; (2) in the same group of patients, free and total urinary carnitine excretion was significantly higher than in normal subjects; (3) administration of high doses of L-carnitine considerably increased urinary excretion of long and short chain carnitine esters; (4) this metabolic effect might explain the reduction in premature ventricular beats on the second day of treatment.

Key Words: Acute myocardial infarction • serum carnitine • urinary camitine • arrhythmias • L-carnitine treatment


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann. N. Y. Acad. Sci.Home page
R. FERRARI, E MERLI, G CICCHITELLI, D MELE, A FUCILI, and C CECONI
Therapeutic Effects of l-Carnitine and Propionyl-l-carnitine on Cardiovascular Diseases: A Review
Ann. N.Y. Acad. Sci., November 1, 2004; 1033(1): 79 - 91.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
R Lango, R.T Smolenski, M Narkiewicz, J Suchorzewska, and W Lysiak-Szydlowska
Influence of L-carnitine and its derivatives on myocardial metabolism and function in ischemic heart disease and during cardiopulmonary bypass
Cardiovasc Res, July 1, 2001; 51(1): 21 - 29.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
D. Bonnet, D. Martin, Pascale de Lonlay, E. Villain, P. Jouvet, D. Rabier, M. Brivet, and J.-M. Saudubray
Arrhythmias and Conduction Defects as Presenting Symptoms of Fatty Acid Oxidation Disorders in Children
Circulation, November 30, 1999; 100(22): 2248 - 2253.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
V. A. Keller, B. Toporoff, R. M. Raziano, J. D. Pigott, and N. L. Mills
Carnitine supplementation improves myocardial function in hearts from ischemic diabetic and euglycemic rats
Ann. Thorac. Surg., November 1, 1998; 66(5): 1600 - 1603.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.